Aura Biosciences Inc (AURA) Price & Analysis

Compare

286 Followers

AURA Stock Chart & Stats

$5.51

-$0.11(-1.36%)

At close: Jan 08 4:00 PM EST

$5.51

-$0.11(-1.36%)

Day’s Range― - ―

52-Week Range$4.35 - $7.73

Previous CloseN/A

Volume82.15K

Average Volume (3M)188.20K

Market Cap

$374.03M

Enterprise Value$344.24M

Total Cash (Recent Filing)$161.87M

Total Debt (Recent Filing)$17.75M

Price to Earnings (P/E)―

Beta1.66

Next Earnings

Mar 31, 2026

EPS Estimate

-0.43

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.40

Shares Outstanding63,503,270

10 Day Avg. Volume203,689

30 Day Avg. Volume188,204

Financial Highlights & Ratios

PEG Ratio0.50

Price to Book (P/B)2.69

Price to Sales (P/S)0.00

P/FCF Ratio-5.03

Enterprise Value/Market Cap0.92

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-386.35

Enterprise Value/Ebitda-3.23

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-1.86

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical TrialsRobust Phase 3 CoMpass enrollment progress and a clear plan for a pivotal topline readout create a visible value inflection that could boost the stock if primary endpoints are met.

Market OpportunityDevelopment of bel-sar across multiple ocular oncology indications and an estimated addressable pool of over 60,000 annual cases in key markets suggest meaningful franchise and revenue potential.

Regulatory DesignationsOrphan Drug and Fast Track designations from major regulators for bel-sar signal regulatory alignment and could accelerate development and commercial opportunities.

Bears Say

Binary Trial RiskHeavy reliance on the pivotal Phase 3 CoMpass readout makes the company vulnerable to a single negative outcome that could sharply reduce valuation despite encouraging early data.

Competitive LandscapeA crowded late-stage NMIBC field and a significant competitor in uveal melanoma for larger tumors could limit market share and pricing power for bel-sar.

Financial RunwayApproximately 1.5 years of cash remaining creates financing risk and may necessitate capital raises that could dilute existing shareholders if non-dilutive options are insufficient.

Aura Biosciences Inc News

Aura Biosciences Expands Evidence With New Patient-Reported Outcome Study in Eye Cancer

Aura Biosciences Inc ($AURA) announced an update on their ongoing clinical study. The Choroidal Melanoma Patient-Reported Outcome Study...

11d ago

AURA

Innovative Approach and Promising Data Drive Buy Rating for Aura Biosciences

Evercore ISI analyst Jonathan Miller has maintained their bullish stance on AURA stock, giving a Buy rating on...

3M ago

AURA

Aura Biosciences re-initiated with an Outperform at Evercore ISI

Evercore ISI re-initiated coverage of Aura Biosciences (AURA) with an Outperform rating and $13 price target Aura uses...

3M ago

AURA

Buy Rating on Aura Biosciences Inc. Driven by Promising Pipeline and Strategic Expansion in Ocular Oncology

Analyst Oliver McCammon of LifeSci Capital maintained a Buy rating on Aura Biosciences Inc, with a price target...

4M ago

AURA

Aura Biosciences Reports Q3 2025 Financial Results

Aura Biosciences Inc ( ($AURA) ) has released its Q3 earnings. Here is a breakdown of the information...

4M ago

AURA

Positive Outlook for Aura Biosciences Inc: Strong Financial Position and Promising Clinical Progress Justify Buy Rating

TD Cowen analyst Phil Nadeau has maintained their bullish stance on AURA stock, giving a Buy rating today....

4M ago

AURA

Aura Biosciences Inc: Strong Buy Rating Backed by Promising Clinical Progress and Strategic Oncology Expansion

In a report released today, Andres Y. Maldonado from H.C. Wainwright reiterated a Buy rating on Aura Biosciences...

4M ago

AURA

Aura Biosciences Reports Q3 2025 Financial Results

Aura Biosciences Inc ( ($AURA) ) has issued an update. On November 13, 2025, Aura Biosciences reported its...

4M ago

AURA

Aura Biosciences reports Q3 EPS (40c), consensus (47c)

“In the third quarter, we remained focused on clinical execution in both our global Phase 3 CoMpass trial...

4M ago

AURA

Aura Biosciences announces cash to fund operations into 1H of 2027

As of September 30, 2025, the Company had cash and cash equivalents and marketable securities totaling $161.9 million....

4M ago

AURA

Aura Biosciences Advances Bladder Cancer Treatment with AU-011 Study

Aura Biosciences Inc (($AURA)) announced an update on their ongoing clinical study. Aura Biosciences Inc. is conducting a...

4M ago

AURA

Aura Biosciences Advances Eye Cancer Treatment with Phase 2 Trial Update

Aura Biosciences Inc (($AURA)) announced an update on their ongoing clinical study. Aura Biosciences Inc. is conducting a...

4M ago

AURA

Aura Biosciences’ Phase 3 Trial: A Potential Game-Changer in Ocular Melanoma Treatment

Aura Biosciences Inc (($AURA)) announced an update on their ongoing clinical study. Aura Biosciences Inc (AURA) is conducting...

4M ago

AURA

Aura Biosciences reports Q2 EPS (47c) vs (41c) last year

“We continued to focus on execution in our clinical programs in the second quarter, including our ongoing global...

7M ago

AURA

AURA FAQ

What was Aura Biosciences Inc’s price range in the past 12 months?

Aura Biosciences Inc lowest stock price was $4.34 and its highest was $7.73 in the past 12 months.

What is Aura Biosciences Inc’s market cap?

Aura Biosciences Inc’s market cap is $374.03M.

When is Aura Biosciences Inc’s upcoming earnings report date?

Aura Biosciences Inc’s upcoming earnings report date is Mar 31, 2026 which is in 29 days.

How were Aura Biosciences Inc’s earnings last quarter?

Aura Biosciences Inc released its earnings results on Nov 13, 2025. The company reported -$0.4 earnings per share for the quarter, beating the consensus estimate of -$0.464 by $0.064.

Is Aura Biosciences Inc overvalued?

According to Wall Street analysts Aura Biosciences Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Aura Biosciences Inc pay dividends?

Aura Biosciences Inc does not currently pay dividends.

What is Aura Biosciences Inc’s EPS estimate?

Aura Biosciences Inc’s EPS estimate is -0.43.

How many shares outstanding does Aura Biosciences Inc have?

Aura Biosciences Inc has 63,503,270 shares outstanding.

What happened to Aura Biosciences Inc’s price movement after its last earnings report?

Aura Biosciences Inc reported an EPS of -$0.4 in its last earnings report, beating expectations of -$0.464. Following the earnings report the stock price went down -0.718%.

Which hedge fund is a major shareholder of Aura Biosciences Inc?

Currently, no hedge funds are holding shares in AURA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Aura Biosciences Inc Stock Smart Score

Underperform

Fundamentals

Return on Equity

-64.26%

Trailing 12-Months

Asset Growth

-7.46%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Aura Biosciences Inc

Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.